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Surgical excision is the preferred treatment for multiple endocrine neoplasia type 1 (MEN1)‑related 
primary hyperparathyroidism (PHPT), although controversy regarding the surgical strategy exists. We 
retrospectively investigated the short‑term outcomes of PHPT by various surgical extents. Thirty‑
three patients who underwent parathyroidectomy due to MEN1‑related PHPT at Yonsei Severance 
Hospital between 2005 and 2018 were included (age [mean ± SD], 43.4 ± 14.1 [range, 23–81] years). 
Total parathyroidectomy with auto‑transplantation to the forearm (TPX) was the most common 
surgical method (17/33), followed by less‑than‑subtotal parathyroidectomy (LPX; 12/33) and subtotal 
parathyroidectomy (SPX; 4/33). There was no postoperative persistent hyperparathyroidism. 
Recurrence was high in the LPX group without significance (1 in TPX, 2 in SPX, and 3 in LPX, p = 0.076). 
Permanent and transient hypoparathyroidism were more common in TPX (n = 6/17, 35.3%, p = 0.031; 
n = 4/17, 23.5%, p = 0.154, respectively). Parathyroid venous sampling (PVS) was introduced in 2013 for 
preoperative localisation of hyperparathyroidism at our hospital; nine among 19 patients operated on 
after 2013 underwent pre‑parathyroidectomy PVS, with various surgical extents, and no permanent 
hypoparathyroidism (p = 0.033) or post‑LPX recurrence was observed. Although TPX with auto‑
transplantation is the standard surgery for MEN1‑related PHPT, surgical extent individualisation is 
necessary, given the postoperative hypoparathyroidism rate of TPX and feasibility of PVS.
Multiple endocrine neoplasia type 1 (MEN1) is a rare, hereditary, multiple endocrine tumour syndrome, mainly 
manifesting as primary hyperparathyroidism (PHPT) in 90% of  patients1. Surgical excision of the affected para-
thyroid glands is the treatment of choice for MEN1-related  PHPT2. The ultimate purpose of parathyroidectomy 
is to normalise serum calcium levels. However, the optimal extent of parathyroidectomy remains controversial, 
with most surgeons advocating for total parathyroidectomy (TPX) with heterotopic auto-transplantation or 
subtotal parathyroidectomy (SPX; 3–3.5 glands).
Heterogeneity of the parathyroid glands in MEN1 patients has been widely  investigated3,4, and the findings 
emphasise the need for individualised minimal surgery. Less-than-subtotal parathyroidectomy (LPX) has increas-
ingly gained support for its lesser associated incidence of postoperative permanent hypoparathyroidism, which 
enables improved quality of life in selected  patients5,6. A precise preoperative localisation technique is crucial for 
successful LPX. Several studies have reported the efficacy of preoperative ultrasound(US), 99mTc-MIBI SPECT/
CT (99mTc-methoxyisobutylisonitrile single photon emission computed tomography/computed tomography), or 
4-dimensional computed tomography (4DCT) for a targeted  approach1,5. Unlike the above mentioned preopera-
tive localisation techniques, parathyroid venous sampling (PVS) is an invasive technique that has mainly been 
used in patients with ambiguous results on preoperative localisation studies or persistent hyperparathyroidism 
after initial  surgery7,8. However, a role for PVS in initial surgery is  emerging9,10. In MEN1-related PHPT, the 
feasibility of PVS for preoperative localisation needs to be clarified.
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In this study, we compared the short-term surgical outcomes of MEN1-related PHPT according to various 
surgical extents at a single tertiary-care hospital. We described our early results with the use of preoperative PVS.
Material and methods
We retrospectively included 33 patients who underwent parathyroidectomy for MEN1-related PHPT at Yonsei 
Severance Hospital (Seoul, Korea) between 2005 and 2018. All patients had a postoperative follow-up of at least 
12 months. Thirty-two patients had been diagnosed by MEN1 gene mutation whereas one patient was diagnosed 
by a first-degree family history of MEN1 with more than two of the major clinical manifestations of  MEN12 (e.g., 
primary hyperparathyroidism, pituitary adenoma, and enteropancreatic tumour). Clinicopathologic factors such 
as age, sex, MEN1 gene mutation status, family history of MEN1, laboratory results, findings of preoperative 
imaging study, and pathology of excised parathyroid glands were reviewed from patient medical records and 
pathology reports.
Patients were divided into three groups by the surgical extents, which were preoperatively and intraopera-
tively determined by the surgeon. Thymectomy was performed only when inferior parathyroid glands were not 
clearly identified during neck exploration. Frozen section of excised specimen during operation for confirm the 
diagnosis was made in such casese. Patients with bilateral lesions on preoperative studies underwent bilateral 
neck exploration; while patients with four or more enlarged glands in the operative field underwent TPX and 
heterotopic auto-transplantation. Patients with a history of previous parathyroidectomy underwent TPX for com-
plete resection of all remnant parathyroid glands followed by auto-transplantation. For auto-transplantation, the 
surgeon selected a gland with minimal hyperplastic changes from among the resected specimens and preserved 
it in cold saline in a sterile manner during the parathyroidectomy. After parathyroidectomy, the preserved para-
thyroid gland was minced into small pieces and injected into the brachioradialis muscle of the non-dominant 
forearm. Patients who preoperatively and intraoperatively had three enlarged glands underwent SPX. The whole 
or half of a single normal gland was marked with a clip and left in situ. LPX was conducted when there was 
definite evidence of two or less affected glands.
Since 2013, PVS has been added to the preoperative localisation study protocol. Figure 1 shows the flow of 
examination and decision making for the surgical extent.
Ten patients who had confirmed bilateral presence of three or more lesions via US and MIBI scans did not 
undergo PVS and directly underwent TPX. Nine patients with ambiguous results or one or two lesions on US 
and MIBI scans underwent PVS. LPX was undertaken when results of all three localisation studies were con-
cordant. If the results of the studies were not concordant or showed bilaterality with three or more lesions, then 
TPX was performed.
Intraoperative parathyroid hormone (PTH) monitoring was undertaken in all patients except in two of 
the early cases. Blood samples were obtained from the radial arterial line 5–15 min after the delivery of each 
specimen. A more than 50% decrease of PTH from the baseline value (preoperative PTH measured on the day 
before surgery) was considered as the criteria for termination of  surgery11. Definitions of recurrence, persistent 
hyperparathyroidism, and transient and permanent hypoparathyroidism were adopted from Horiuchi et al.12 
Both normocalcemic and hypercalcemic high PTH levels occurring after a minimum of 6 months of the normal 
postoperative period were defined as recurrence, whereas persistent disease was defined as non-normalisation 
Figure 1.  Schematic representation of decision making of the surgical extent after the introduction 
of parathyroid venous sampling (PVS). TPX, total parathyroidectomy with auto-transplantation to the 
forearm; SPX, subtotal parathyroidectomy; LPX, less-than-subtotal parathyroidectomy; MIBI, 99mTc-
methoxyisobutylisonitrile single photon emission computed tomography; US, Ultrasonography.
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of PTH and serum calcium postoperatively. The cut-off value between transient and permanent hypoparathy-
roidism after surgery was 6 months.
A chi-squared or Fisher’s exact test was used to compare categorical data. For continuous data, an ANOVA 
or Kruskal–Wallis test was used. All data were analysed with IBM SPSS Statistics ver. 22.0 (IBM, Armonk, NY, 
USA). A p-value < 0.05 was considered statistically significant. The study protocol was approved by the institu-
tional review board (IRB) of the Yonsei University College of Medicine (IRB No. 4–2020-0,014). The research 
was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.
Results
Patient characteristics are presented in Table 1. There were no intergroup differences in age and follow-up period 
among the three groups. Preoperative intact PTH level was highest in the TPX group (p = 0.017), followed by 
those in the SPX and LPX groups. There were 26 germline mutations in a total of 32 patients. Most mutations 
were found in exon 2 (11/32, 34.38%).
Surgical outcomes are presented in Table 2. There was no persistent hyperparathyroidism after surgery. All 
instances of transient and permanent hypoparathyroidism occurred in the TPX group. Among six patients 
who developed postoperative permanent hypoparathyroidism, three recovered within 35 months after surgery 
(recovery period range: 19–35 months). The number of recurrences was highest in the LPX group but was not 
statistically significant (p = 0.076).
Considering these outcomes together, TPX had a significantly high complication rate (p = 0.001). All recur-
rences in the SPX and LPX groups occurred in glands that were not resected. In one case of TPX, a rising trend 
of PTH without definite suspicious imaging findings was noted. Recurrence-free survival of SPX and LPX was 
55 and 44 months, respectively. All intraoperative quick PTH levels measured at 15 min after the delivery of the 
last specimen were in the normal range, regardless of the surgical extent of resection. Although the mean PTH 
level was highest in the LPX group, this was not statistically significant (p = 0.357).
In 2013, PVS was introduced at our hospital. PVS was performed to patients with one or two enlarged para-
thyroid glands identified on preoperative US and 99mTc-MIBI SPECT/CT. Consistent results of all three of pre-
operative localisation studies were considered as an appropriate incdication for LPX. Table 3 shows the detailed 
results of preoperative localisation studies, surgical extent and its associations with pathology in PVS group.
Table 4 presents the results of preoperative PVS; the PVS group showed no persistent hyperparathyroidism 
or permanent hypoparathyroidism postoperatively. There was no recurrence even after LPX.
Table 1.  Patients characteristics. Data are presented as median or mean ± SD, *p < 0.05. TPX total 
parathyroidectomy, SPX subtotal parathyroidectomy, LPX less-than-subtotal parathyroidectomy. Other MEN1 
Sx includes pancreatic neuroendocrine tumour and pituitary adenoma.
Total TPX SPX LPX p value
No. of patients 33 17 4 12






(37.4 ± 8.9) 0.135


























(108.8 ± 37.7) 0.017*
Genetically confirmed 31 (93.9%) 17 (100%) 3 (75%) 11 (91.7%) 0.227
Other MEN1 Sx 28 (84.8%) 16 (94.1%) 4 (100%) 8 (66.7%) 0.131
No. preoperative
-detected parathyroid 2.0 (1.9) 2.0 (2.1 ± 0.7) 3.0 (2.8 ± 0.5) 1.0 (1.4 ± 0.5) 0.001*
No. intraoperative-confirmed abnormal parathyroid 3.0 (3.0) 4.0 (4.1 ± 0.9) 3.3 (3.3 ± 0.3) 1.5 (1.5 ± 0.5) 0.000*
No. pathologically confirmed adenoma/hyperplasia 4.0 (3.0) 4.0 3.0 (2.8 ± 1.3) 1.0 (1.4 ± 0.5) 0.000*
Auto-transplantation 17 (51.5%) 17 (100%) 0 (0) 0 (0) 0.000*
Thymectomy 11 (33.3%) 10 (58.8%) 0 (0) 1 (9.1%) 0.004*
Table 2.  Surgical outcomes according to the surgical extent. TPX total parathyroidectomy with auto-
transplantation to the forearm, SPX subtotal parathyroidectomy, LPX less-than-subtotal parathyroidectomy.
Total (n = 33) TPX (n = 17) SPX (n = 4) LPX (n = 12) p value
Persistent hyperparathyroidism 0 0 0 0 NA
Transient hypoparathyroidism 4 (12.1%) 4 (23.5%) 0 0 0.154
Permanent hypoparathyroidism 6 (18.2%) 6 (35.3%) 0 0 0.031*
Recurrence 6 (35.3%) 1 (5.9%) 2 (50%) 3 (25%) 0.076
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Discussion
MEN1 is caused by a germline-inactivating mutation of the tumour suppressor gene, MEN1, located on chro-
mosome 11q13, which encodes the menin protein, an important transcriptional regulatory  factor13,14. There are 
more than 1,000 known germline mutations that can cause  MEN114. As every gland has the same potential risk 
of hyperplasia due to those genetic alterations, TPX with heterotopic auto-transplantation is considered the 
eventual surgical method for MEN1-related PHPT.
TPX may be the only curative surgery for MEN1-related PHPT; however, permanent hypoparathyroidism 
is a major complication that is more troubling than disease recurrence. Nonetheless, there is no effective way 
to intraoperatively evaluate the viability of the auto-transplantated parathyroid gland. SPX was proposed as a 
feasible alternative method to replace  TPX15. However, the rate of permanent hypoparathyroidism after SPX 
has not improved significantly compared to that after  TPX1. The range of permanent hypoparathyroidism in 
the SPX group was reported as 0–40%12. Lorente-Poch at el. reported that auto-transplantation of the acciden-
tally resected fourth parathyroid gland could not prevent the occurrence of permanent hypoparathyroidism 
Table 3.  Detailed description of preoperative localisation studies and pathological results. TPX total 
parathyroidectomy with auto-transplantation to the forearm, SPX subtotal parathyroidectomy, LPX less-
than-subtotal parathyroidectomy, MIBI 99mTc-methoxyisobutylisonitrile single photon emission computed 
tomography, US ultrasonography, PVS parathyroid venous sampling, Rt. right, Lt. left.
Lesions found at US & MIBI Lesions found at PVS Surgical extent Pathologically positive lesion
Case 1










Rt. inferior Rt. inferior Rt. inferior














Rt. inferior Rt. inferior
Lt. superior Lt. superior Lt. superior
Lt. inferior Lt. inferior
Case 5
Rt. superior Rt. superior
SPX
Rt. superior
Rt. inferior Rt. inferior
Lt. superior Lt. superior Lt. superior
Case 6 Ambiguous Rt. superior LPX Rt. superior
Case 7 Rt. inferior Rt. inferior LPX Rt. inferior
Case 8
Rt. superior Rt. superior
LPX
Rt. superior
Rt. inferior Rt. inferior Rt. inferior
Case 9
Rt. inferior Rt. inferior
LPX
Rt. inferior
Lt. superior Lt. superior Lt. superior
Table 4.  Surgical outcomes according to preoperative parathyroid venous sampling. PVS parathyroid venous 
sampling, TPX total parathyroidectomy with auto-transplantation to the forearm.
PVS (n = 9) Non-PVS (n = 10) p value
Persistent hyperparathyroidism 0 0 NA
Transient hypoparathyroidism 2 (22.2%) 1 0.582
Permanent hypoparathyroidism 0 5 (50%) 0.033*
Recurrence 0 1 (10%) 1.000
TPX 4 (44.4%) 10 (100%) 0.011*
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in total  thyroidectomy16. The risk of permanent hypoparathyroidism after total thyroidectomy is well known. 
Bergenfelz et al. and Almquist et al. reported that permanent hypoparathyroidism was not only associated 
with an increased risk of renal insufficiency, malignancies, and cardiovascular events but also with increased 
 mortality17,18. Although these studies were conducted on patients with normal parathyroid glands, a similar 
pathophysiology may be applied to parathyroidectomy after MEN1-related hyperparathyroidism.
The concept of limited surgery in MEN1-related PHPT was presented to overcome the permanent hypopar-
athyroidism after TPX. This first originated from the premise that all glands are not simultaneously enlarged, and 
it may not be necessary to eliminate all the glands at once. The size heterogeneity of parathyroid glands in MEN1 
is well  known3. This hypertrophy of glands is associated with hyperfunction. In our study, preoperative PTH was 
highest in the TPX group, which had the largest number of enlarged parathyroid glands identified, followed by 
the SPX and LPX groups. This phenotypic asymmetricity can be explained by the independent occurrence of a 
“second hit” somatic mutation of the MEN1 gene in the four parathyroid  glands1. Marini et al. reported incom-
plete penetrance of menin mutations. They analysed 410 MEN1 patients including 370 familial cases. Despite 
the presence of the same genetic mutation within the same pedigree, patients showed varying degree of severity 
of clinical  symptoms19. Pardi et al. also found an absence of genotype–phenotype correlation in  MEN120. These 
findings suggest that patients can be categorised by the number of preoperatively enlarged parathyroid glands, 
which is correlated with disease severity.
In selected patients with a limited number of enlarged glands, less aggressive surgery may be sufficient. 
Several reports support this theory, and conclude that the excision of only enlarged glands could achieve long-
term recurrence-free  survival6,21. As MEN1-related PHPT is known to develop at a younger age than sporadic 
 PHPT2, this is an especially important result for younger patients. A focused approach is known to not only 
reduce the operation time, incision size, hospital stay, and postoperative pain, but also to lower the incidence 
of postoperative permanent  hypocalcemia22. The results of our data are consistent with previous studies. When 
LPX was conducted in appropriately selected patients, it showed the least incidence of transient or permanent 
postoperative hypoparathyroidism, with acceptable recurrence rates compared with that of TPX or SPX. The 
intraoperative PTH levels normalised in all patients after the excision of enlarged glands and there was no per-
sistent hyperparathyroidism.
In addition to the low permanent hypoparathyroidism rate, LPX has another strong advantage. Considering 
the higher risk of reoperation in patients with MEN1 than in patients with sporadic primary hyperparathy-
roidism, limited exploration has the benefit of facilitating future surgery via preservation of an unresected area. 
Blind bilateral neck exploration can cause wide extensive postoperative adhesion, which poses difficulties to 
reoperation. In our data, all the recurrences of the SPX and LPX groups occurred in unresected glands. A previ-
ously untouched operation field made it easy to excise the remnant enlarged glands and there was no reoperation-
related recurrent laryngeal nerve injury or prolongation of operation time, compared to the initial surgery (data 
not shown). In clinical practice, a ‘staged operation’ followed by initial LPX may be a more appropriate concept 
for MEN1-PHPT in select patients given the balance between potential risks of recurrence and consequences 
of permanent  hypoparathyroidism6.
For successive LPX, the selection of indicated patients is important. Elaboration of preoperative imaging 
techniques has been largely implicated in the increased success rate. Thus far, 99mTc-MIBI SPECT/CT scans 
have been the modality of choice. However, 99mTc-MIBI SPECT/CT has several limitations. False-negative or 
positive results can occur due to small parathyroid adenomas, multiglandular disease, or the presence of thyroid 
 nodules23. High-resolution US is useful to understand the anatomic relation between parathyroid glands and the 
adjacent thyroid gland. Although US alone is not enough for preoperative evaluation due to its low sensitivity 
and  specificity24, a combination of 99mTc-MIBI SPECT/CT and US has been a popular method for preoperative 
localisation of PHPT.
However, surgeons hesitate to plan LPX for MEN1 patients even when both US and MIBI have identified one 
or two enlarged glands. With PVS, surgeons can decide on LPX with greater confidence. In our study, concordant 
results of 99mTc-MIBI SPECT/CT, US, and PVS were highly predictive for successful LPX. Four patients who had 
undergone LPX would have undergone TPX if they were operated on prior to 2013. By adding PVS for preop-
erative localisation and intraoperative quick PTH monitoring for intraoperative evaluation for determine the 
termination of surgery, the incidence of persistent hyperparathyroidism after LPX can be effectively lowered. PVS 
was also useful in identifying parathyroid lesions which were missed at previous conventional preoperative imag-
ing studies. In four of five non-concordant cases, PVS detected more lesions than US and 99mTc-MIBI SPECT/
CT. Six of nine additional lesions newly found at PVS was pathologically positive for parathyroid adenoma or 
parathyroid hyperplasia. Lee et al. also reported the discriminative power of PVS for localise parathyroid lesions 
in patients with negative findings in conventional US and 99mTc-MIBI SPECT/CT10.
The most important concern of PVS is radiation exposure. According to our data, the radiation exposure 
of PVS ranges from 1.23 to 5.8 mSv, which was half of that from 4DCT (10.4 mSv) and lower than MIBI 
(6.7–7.8 mSv)10.
This study has several limitations. It was conducted in a retrospective manner with a limited number of 
patients. MEN1 is a rare disease, so only 33 patients were treated at our hospital over the past 13 years, despite our 
hospital being a large tertiary referral center for endocrine surgery. This is not very different from other published 
data(24–28 patients, over 20–28 years)5,6,16. The median follow-up period was relatively short (58 months). Time 
to recurrence after parathyroidectomy varies among reports, from 1 to  26years5,6,25. Although our patients might 
eventually recur with time, this study showed the benefit of LPX in managing current hyperparathyroidism while 
avoiding or defer permanent hypoparathyroidism. Our study supports the trend of paradigm shift of reoperation 
in MEN1-related hyperparathyroidism patients from ‘surgical failure’ to ‘strategic staged operation’. With longer 
follow-up periods, recurrence free survival of LPX group in our data(44 months) is expected to be changed. 
Further consensus is needed on how long the period without recurrence after surgery should be achieved to 
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determine LPX as an feasible procedure for MEN1-related PHPT. The surgical extent was decided differently 
by the surgeon’s preference. The time gap between the introduction of PVS could be problematic. Nonetheless, 
this is the first study to have evaluated the efficacy of PVS in MEN1-related PHPT. Thus, adding PVS in selected 
patients with MEN1-related PHPT may be helpful to decide on safe and effective limited parathyroidectomy. 
These findings need to be validated in future larger sample studies.
Conclusion
TPX with auto-transplantation has been considered the standard surgical treatment for MEN1-related PHPT. 
However, considering the significant postoperative hypoparathyroidism rate associated with TPX and the fea-
sibility of PVS, individualised decisions regarding the surgical extent of resection in MEN1-related PHPT is 
important.
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